A Wave of Hope: States Mandate Insurance for Scalp Cooling Therapy

HOUSTON, TX – March 12, 2026 – A groundswell of legislative action is sweeping across the United States, aiming to redefine a crucial aspect of cancer care. Following the successful enactment of insurance mandates in New York and Louisiana this January, eleven additional states are now advancing bills to require coverage for scalp cooling therapy, a clinically proven method to help prevent the devastating hair loss associated with chemotherapy. This nationwide push signals a profound shift in how policymakers and insurers view the management of treatment side effects, moving them from the periphery to the center of comprehensive patient care.

At the heart of this movement is a technology that, for many patients, offers a lifeline to normalcy during an otherwise tumultuous journey. Companies like Paxman, a global leader in the field, have developed systems that work by cooling the scalp to a low temperature before, during, and after chemotherapy infusion. This process constricts blood vessels beneath the skin, reducing the amount of chemotherapy drugs that reach the hair follicles and thereby preserving the hair. The legislative efforts, strongly supported by Paxman and a coalition of patient advocates and clinicians, aim to dismantle the significant financial barriers that have historically kept this option out of reach for many.

"Insurance coverage is essential to expanding patient access while reducing financial barriers," said Richard Paxman, Chief Executive Officer of Paxman, in a recent statement. "This progress aligns with our mission to minimize the impact of cancer treatment on patients' lives and reflects a growing recognition of the importance of side effect management."

A Human-Centered Approach to Cancer Care

For countless individuals undergoing chemotherapy, the prospect of losing their hair—a condition known as chemotherapy-induced alopecia—is more than a matter of vanity. It is a profound and often traumatic experience that serves as a constant, public reminder of their illness. This visible side effect can deeply impact a patient's mental health, self-esteem, and sense of identity, adding a significant emotional burden to an already grueling physical fight.

"For many cancer patients, losing their hair is one of the most visible and emotionally difficult parts of chemotherapy," noted Maryland Delegate LaToya Nkongolo, a sponsor of her state's successful bill. The sentiment is echoed in patient testimonies submitted in legislative hearings across the country. Advocates describe how the ability to retain their hair allowed them to maintain privacy about their diagnosis, continue working without unwanted questions, and feel more like themselves rather than just a cancer patient. For some, the fear of hair loss is so intense that it can influence their decisions about pursuing life-saving treatment.

This legislative wave is a direct response to years of advocacy from patient groups like the Rapunzel Project and individual survivors who have shared their stories. They argue that supportive care that preserves a patient's quality of life and mental well-being is not an elective luxury but a medical necessity. By mandating insurance coverage, lawmakers are affirming that the psychological and social impacts of treatment are integral components of a patient's overall health.

The Legislative Domino Effect: From Mandates to Momentum

The current momentum builds on a solid foundation laid by New York and Louisiana, where laws requiring large group insurers to cover scalp cooling took effect on January 1, 2026. Their success has created a clear blueprint for other states.

Maryland is on the cusp of joining them. Legislation (HB 0393 / SB 0272) has passed both the House and Senate with overwhelming bipartisan support. After a final procedural vote, the bill will head to Governor Wes Moore's desk. Similarly, West Virginia's legislature has passed House Bill 4089, which now awaits a decision from Governor Patrick Morrisey. If signed, these bills would mandate coverage starting in 2027.

The movement's reach is extensive. In California, the nation's largest healthcare market, Assembly Bill 1682 has been introduced and referred to the Assembly Health Committee, representing a potentially massive expansion of access. In Rhode Island, companion bills are progressing through the House and Senate. Seven other states—Kentucky, Massachusetts, New Jersey, Ohio, Pennsylvania, South Carolina, and Virginia—all have similar legislation pending, each representing another potential victory for patients.

Delegate Nkongolo expressed a vision that resonates with legislators nationwide: "This legislation ensures patients have access to a clinically proven treatment without added financial burden. We are proud to lead in expanding access and hope even more states will join in this important work."

Standardizing Access: The Critical Role of CPT Codes

Underpinning this state-by-state legislative campaign is a crucial federal development. As of January 2026, new Category I Current Procedural Terminology (CPT®) codes for scalp cooling took effect nationwide. These codes, established by the American Medical Association, create a standardized, universally recognized system for medical practices to bill for the therapy.

Prior to the establishment of these codes, billing was a patchwork of inconsistent practices. Many insurers classified scalp cooling as cosmetic, forcing patients to pay entirely out of pocket, with costs often running between $1,500 and $5,000. This created a significant equity problem, where access to the therapy was largely determined by a patient's ability to pay. The new CPT codes provide the essential mechanism for reimbursement, transforming scalp cooling from a self-pay service to an insurable medical procedure.

While the CPT codes provide the how for reimbursement, the state mandates provide the must. Together, they form a powerful combination that is systematically dismantling the financial barriers to access. This dual-pronged approach is creating a clear and sustainable business model for oncology practices to offer the service, ensuring that the technology can be integrated seamlessly into standard cancer care protocols.

A New Era for Supportive Oncology and Market Growth

The widespread push for scalp cooling coverage represents more than just a victory for a single technology; it heralds a new era for supportive oncology. It reflects a growing consensus that the goal of cancer treatment should not only be to eradicate disease but also to preserve the patient's quality of life throughout the process. This precedent could pave the way for broader coverage of other technologies and services designed to mitigate the harsh side effects of treatment.

The market for scalp cooling technology, once a niche sector, is poised for significant growth. The FDA has cleared devices from several companies, including Paxman, Dignitana, and the more recent entrant Cooler Heads. As insurance coverage becomes the norm, competition and innovation are likely to accelerate, potentially leading to more effective and accessible technologies.

The strategic advocacy by companies like Paxman, working in concert with patients and clinicians, demonstrates a successful model for driving policy change that benefits both patients and the industry. As more states join the movement and insurers adapt to the new landscape, access to scalp cooling therapy is on track to become a standard of care, offering a measure of control and a beacon of hope to thousands of cancer patients across the country.